Holen Sie sich die Stockscreener-App
13.00
6.20%
-0.86
Handel nachbörslich:
12.95
-0.05
-0.38%
Schlusskurs vom Vortag:
$13.86
Offen:
$14.04
24-Stunden-Volumen:
228.11K
Relative Volume:
0.89
Marktkapitalisierung:
$474.88M
Einnahmen:
$50.00M
Nettoeinkommen (Verlust:
$-59.98M
KGV:
-5.9535
EPS:
-2.1836
Netto-Cashflow:
$-55.54M
1W Leistung:
-6.34%
1M Leistung:
-9.97%
6M Leistung:
+5.22%
1J Leistung:
+82.07%
1-Tages-Spanne:
$12.94
$14.38
1-Wochen-Bereich:
$12.94
$15.00
52-Wochen-Spanne:
$3.35
$16.33
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Firmenname
Contineum Therapeutics Inc
Sektor
Branche
Telefon
(858) 333-5280
Adresse
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
13.00 | 506.30M | 50.00M | -59.98M | -55.54M | -2.1836 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-09-25 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-20 | Eingeleitet | William Blair | Outperform |
| 2024-10-22 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-30 | Eingeleitet | Stifel | Buy |
Alle ansehen
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Update Recap: How sensitive is Contineum Therapeutics Inc to inflationQuarterly Profit Review & Daily Chart Pattern Signals - baoquankhu1.vn
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Can Contineum Therapeutics Inc. stock resist sector downturns2026 Institutional & Risk Adjusted Buy and Sell Alerts - Naître et grandir
Contineum Therapeutics (NASDAQ:CTNM) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $20.00 at Robert W. Baird - MarketBeat
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress - The Globe and Mail
Stifel reiterates Buy on Contineum stock, keeps $29 price target - Investing.com South Africa
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Developme - PharmiWeb.com
Stifel reiterates Buy on Contineum stock, keeps $29 price target By Investing.com - Investing.com Canada
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - The National Law Review
Contineum Therapeutics (NASDAQ:CTNM) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Contineum reports Q4 EPS (49c), consensus (39c) - TipRanks
Contineum Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Contineum Therapeutics (NASDAQ: CTNM) posts Q4 loss, adds $100,000,000 at-the-market stock capacity - Stock Titan
According to the latest public documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Contineum Therapeutics Inc. has launched a new stock offering plan. - Bitget
CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
USD News Center - University of San Diego
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
CTNMContineum Therapeutics Latest Stock News & Market Updates - Stock Titan
Contineum Therapeutics to Present at September Investor Conferences - Business Wire
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares By Investing.com - Investing.com Australia
Contineum Therapeutics (CTNM) CMO sells $54,220 in stock - Investing.com
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares - Investing.com
Contineum Therapeutics (CTNM) CMO sells $54,220 in stock By Investing.com - Investing.com UK
Contineum Therapeutics (CTNM) CSO sells shares under 10b5-1 plan - Stock Titan
Contineum Therapeutics (CTNM) CMO sells 3,611 shares via 10b5-1 - Stock Titan
Beat the Market with Zacks: Spotlight on Contineum Therapeutics, Suzano, and PepsiCo - Bitget
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus - Yahoo Finance
Earnings Beat: Is Contineum Therapeutics Inc gaining market shareJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Contineum Therapeutics CSO Lorrain S. Daniel sells $130k in CTNM stock - Investing.com Nigeria
Contineum Therapeutics (CTNM) CEO sells 7,100 shares, exercises options - Stock Titan
Contineum Therapeutics (CTNM) CSO exercises options and sells 8,124 shares - Stock Titan
Contineum Therapeutics (CTNM) Projected to Post Earnings on Thursday - MarketBeat
CTNM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Contineum Therapeutics Inc gaining market shareEarnings Summary Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of “Moderate Buy” by Analysts - Defense World
CTNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Balyasny Asset Management L.P. Increases Stake in Contineum Ther - GuruFocus
Balyasny Asset Management L.P. Increases Stake in Contineum Therapeutics Inc. - GuruFocus
What’s the MACD signal for Contineum Therapeutics Inc.July 2025 Snapshot & Daily Volume Surge Signals - mfd.ru
A | Can IRDM navigate macro headwindsJuly 2025 Movers & Consistent Return Strategy Ideas - mfd.ru
Contineum (NASDAQ: CTNM) CSO trades shares under 10b5-1 plan - Stock Titan
Will Contineum Therapeutics Inc. stock continue dividend increasesJuly 2025 Opening Moves & Verified Momentum Stock Ideas - mfd.ru
RA Capital discloses 7.2% Contineum Therapeutics (CTNM) ownership stake - Stock Titan
Balyasny discloses 7.6% Contineum (CTNM) stake via ADMF fund - Stock Titan
Published on: 2026-02-15 23:21:35 - mfd.ru
Can Contineum Therapeutics Inc. stock outperform in a bear marketTrade Exit Summary & Entry Point Strategy Guides - mfd.ru
Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Finanzdaten der Contineum Therapeutics Inc-Aktie (CTNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):